<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02353715</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00058229</org_study_id>
    <nct_id>NCT02353715</nct_id>
  </id_info>
  <brief_title>Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing</brief_title>
  <acronym>PEAX</acronym>
  <official_title>PEAX: Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot exercise physiology and quality of life study of subjects receiving standard&#xD;
      of care therapy for their prostate cancer using FDA-approved drugs per their labeling&#xD;
      (abiraterone, enzalutamide, or sipuleucel-T). Subjects with progressive, asymptomatic or&#xD;
      minimally symptomatic mCRPC scheduled to be treated with either enzalutamide or abiraterone&#xD;
      acetate for ≥3 months or a course of sipuleucel-T will be allocated to one of the treatments&#xD;
      arms, according to the treatment chosen by the treating physician.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2015</start_date>
  <completion_date type="Actual">November 14, 2018</completion_date>
  <primary_completion_date type="Actual">November 14, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VO2peak from baseline with abiraterone, enzalutamide or sipuleucel-T at week 21</measure>
    <time_frame>baseline, 21 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare VO2peak with patient- and physician reported functional status</measure>
    <time_frame>21 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the variability of CPET in all arms</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">38</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <description>Subjects will be administered enzalutamide per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abiraterone</arm_group_label>
    <description>Subjects will be administered abiraterone acetate per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sipuleucel-T</arm_group_label>
    <description>Subjects will be administered sipuleucel-T per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <arm_group_label>Enzalutamide</arm_group_label>
    <other_name>Xtandi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone acetate</intervention_name>
    <arm_group_label>Abiraterone</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sipuleucel-T</intervention_name>
    <arm_group_label>Sipuleucel-T</arm_group_label>
    <other_name>Provenge</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Duke clinics patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male age ≥ 18 years&#xD;
&#xD;
          2. Histologically-confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          3. Surgically or medically castrated&#xD;
&#xD;
          4. Starting either enzalutamide or abiraterone for at least 12 weeks OR starting a course&#xD;
             of sipuleucel-T. Subjects being treated concomitantly with abiraterone or enzalutamide&#xD;
             plus sipuleucel-T are eligible and should be enrolled on Arm A or Arm B, as&#xD;
             appropriate.&#xD;
&#xD;
          5. ECOG performance status 0 or 1&#xD;
&#xD;
          6. Able to read and understand English, in the opinion of the treating provider, well&#xD;
             enough to complete the study questionnaires&#xD;
&#xD;
          7. Able to comply with study requirements&#xD;
&#xD;
          8. Successful completion of a CPET in the opinion on the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have had any surgical procedure (i.e. TURP, etc.) within 4 weeks prior to&#xD;
             entering the study.&#xD;
&#xD;
          2. Subjects receiving treatment with BOTH abiraterone and enzalutamide&#xD;
&#xD;
          3. For Arm C (sipuleucel-T) only:&#xD;
&#xD;
               1. subjects receiving abiraterone or enzalutamide concomitantly with sipuleucel-T&#xD;
                  should only be enrolled on Arm A or Arm B, as appropriate.&#xD;
&#xD;
               2. subjects who have received prior sipuleucel-T&#xD;
&#xD;
          4. Subjects who are receiving any other investigational agents (i.e. enzalutamide or&#xD;
             abiraterone plus an investigational drug).&#xD;
&#xD;
          5. Subjects with any of the following absolute contraindications to maximal exercise&#xD;
             testing as recommended by the American Thoracic Society and the exercise testing&#xD;
             guidelines for cancer subjects, in the opinion of the treating provider: (a) acute&#xD;
             myocardial infarction (3-5 days), (b) unstable angina, (c) uncontrolled arrhythmias&#xD;
             causing symptoms or hemodynamic compromise, (d) syncope, (e) acute endocarditis, (f)&#xD;
             acute myocarditis or pericarditis, (g) uncontrolled heart failure, (h) acute pulmonary&#xD;
             embolus or pulmonary infarction, (i) thrombosis of lower extremities, (j) suspected&#xD;
             dissecting aneurysm, (k) uncontrolled asthma, (l) pulmonary edema, (m) room air&#xD;
             desaturation at rest &lt;85%, (n) respiratory failure, (o) acute noncardiopulmonary&#xD;
             disorder that may affect exercise performance or be aggravated by exercise, (p) mental&#xD;
             impairment leading to inability to cooperate, and (q) extensive bone metastases.&#xD;
&#xD;
          6. Significant cardiovascular disease, including:&#xD;
&#xD;
               1. Symptomatic left ventricular dysfunction or known baseline left ventricular&#xD;
                  ejection fraction (LVEF) by multigated acquisition scan (MUGA) or echocardiogram&#xD;
                  (ECHO) of &lt; lower limit of institutional normal (LLN). &quot;Symptomatic&quot; is defined&#xD;
                  as New York Heart Association (NYHA) Class II or greater. Note: MUGA and ECHCO do&#xD;
                  NOT need to be measured to establish eligibility for this study.&#xD;
&#xD;
               2. Uncontrolled hypertension&#xD;
&#xD;
               3. Myocardial infarction, severe angina, or unstable angina within 6 months prior to&#xD;
                  administration of first dose of study drug&#xD;
&#xD;
               4. History of serious ventricular arrhythmia (i.e., ventricular tachycardia or&#xD;
                  ventricular fibrillation) within 12 months of first dose of study drug&#xD;
&#xD;
               5. Uncontrolled cardiac arrhythmias&#xD;
&#xD;
               6. Coronary or peripheral artery bypass graft within 6 months of first dose of study&#xD;
                  drug&#xD;
&#xD;
               7. History of CVA, TIA, or rest claudication within 6 months of first dose of study&#xD;
                  drug&#xD;
&#xD;
          7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          8. Known or suspected brain metastasis or leptomeningeal disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Harrison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

